Research Directions Depression
October 13, 2023
Ian B. Hickie, F. Markus Leweke, Allan H. Young
1 citation
In recent years, there has been considerable enthusiasm among research groups focused on developing novel therapies for treatment-resistant depression, and a wider community that has had experiences using recreational drugs, in more systematic evaluation of the therapeutic value of these compounds (Goodwin et al., 2022; Young, 2023). This has also been associated with advocacy for...
BCIT Environmental Public Health Journal
October 12, 2023
Payman Baharmand, Amardeep Kambo
Psilocybin is a naturally occurring hallucinogen found in different species of fungi. Psilocybin has gained extensive social popularity and political attention in the United States. Research has shown that psilocybin and psychological therapy may have promising therapeutic applications for safer and more effective treatment of mental illnesses such as major depressive disorder, addiction,...
October 11, 2023
Stefanie Enriquez‐geppert, Jaroslav Krc, Fiachra O'Higgins et al.
1 citation
preprint
Executive function deficits, common in psychiatric disorders, hinder daily activities and may be linked to diminished neural plasticity, affecting treatment and training responsiveness. In this pioneering study, we evaluated the feasibility and preliminary efficacy of psilocybin-assisted frontal-midline theta neurofeedback (NF), a neuromodulation technique leveraging neuroplasticity, to improve...
Georgetown Scientific Research Journal
October 10, 2023
Anna Douglas, Daniel Staas, Anna Hampton et al.
1 citation
Depression remains one the most commonly diagnosed mental health disorders in the United States. The Food and Drug Administration granted psilocybin breakthrough therapy status four years ago as a possible solution to this pervasive disorder. Since then, psilocybin, and hallucinogens in general, have produced promising results as alternatives to classical antidepressants. As more research...
Journal of Psychoactive Drugs
October 10, 2023
Ashmita Grewal, Kalysha Closson, Gina Martin et al.
11 citations
Survivors of adverse childhood experience are at elevated risk for psychological distress. In recent years, renewed interest in psychedelic medicine has highlighted the therapeutic potential of psilocybin for those who have experienced childhood adversity. However, recreational psilocybin use remains illegal and access to approved therapies is difficult. Such use provides an opportunity to...
The Brown University Psychopharmacology Update
October 4, 2023
Ongoing antidepressant treatment is believed to alter the psychedelic effect of psilocybin, so most psilocybin trials have required withdrawal from antidepressants before enrollment. There has been recent evidence, however, that administration of a selective serotonin reuptake inhibitor (SSRI) does not significantly alter the acute subjective effects of psilocybin. A Phase 2 open-label trial...
Expert Opinion on Investigational Drugs
October 3, 2023
Zofia Kozak, Matthew W Johnson, Scott T Aaronson
10 citations
There is still much unknown regarding the risks of psilocybin treatment. When weighing the known risks and benefits of psilocybin treatment against those found in existing standards of care, among patients with depression, patients with treatment-resistant depression (TRD) may be the most suitable candidates for psilocybin treatment at this time.
Expert Opinion on Emerging Drugs
October 2, 2023
Katarzyna Śladowska, Paweł Kawalec, Tomasz Brzostek et al.
4 citations
Clinical phase I-II trials published to date reported promising results for psilocybin in the treatment of patients with major depressive disorder and treatment-resistant depression, in a relatively short time after administration. However, before psilocybin is approved for use and administered to patients with depression, the results of large ongoing phase III clinical trials are needed to...
IBRO Neuroscience Reports
October 1, 2023
Chloé Galipeau, Miguel Farinha‐ferreira, Jean-Charles Rene’ Pasquin Mariani et al.
Psilocybin is a 5-HT2AR agonist, responsible for the psychoactive effects of psychedelic mushrooms, which has recently shown therapeutic potential for several conditions, including major depressive disorder. However, the mechanisms underlying this effect, and the possibility of dissociating the psychedelic and antidepressant actions of psilocybin, remain undetermined, with preclinical research...
IBRO Neuroscience Reports
October 1, 2023
Ines Erkizia-Santamaría, J. Javier Meana, Igor Horrillo et al.
Long-term exposure to stress is associated to HPA axis alterations and the development of depression. Chronic unpredictable mild stress (CUMS) is a widely used and validated animal model of depression, and presents phenotypic features of this disease, like anhedonia and despair, along with physiological and neurochemical alterations. Recently, the psychedelic 5-HT2A agonist psilocybin has...